⁍ AstraZeneca has signed multiple supply-and-manufacture deals for more than 3 billion doses globally.
⁍ The vaccine is expected to be one of the first from big pharma to secure regulatory approval.
⁍ AstraZeneca resumed the U.S. trial of its experimental COVID-19 vaccine after approval by regulators.
– Drugmaker AstraZeneca says it will have to fork over up to 20% of the manufacturing costs for an experimental vaccine designed to fight the H7N9 virus, reports the Wall Street Journal. The move is in response to the $1 billion the company says it will have to spend to develop and manufacture the vaccine, as well as the hundreds of millions more it will have to spend during the H7N9 outbreak if it can’t get access to the vaccine in time. “To cover these additional expenses, the company will add an amount equivalent to a maximum of 20% of the manufacturing costs to ensure there is no material impact on its finances this year while continuing efforts to provide the vaccine at no profit during the pandemic,” AstraZeneca said in a statement, per Reuters.
Source: https://www.reuters.com/article/us-health-coronavirus-astrazeneca-vaccin/astrazeneca-says-its-oxford-vaccine-deal-allows-it-to-add-up-to-20-of-manufacturing-costs-idUSKBN2782WC